Home Companies Catalysts Deep Dives
Tecvayli teclistamab APPROVED
Drug Profile
ModalityBispecific
RouteSC
Therapy AreaOncology
Launch2022-10-25
US LOE2034-10-25
Peak Sales Est$2500M
Formulations[{"id":"tecvayli-sc","route":"SC","setting":"OFFICE","frequency":"Weekly","is_primary":true}]
Companies
JNJ (LICENSEE)0%
GMAB (ROYALTY)0%
Mechanism: BCMAxCD3 bispecific
Expert: Bispecific T-cell engager binding BCMA on myeloma cells and CD3 on T-cells, inducing T-cell mediated cytotoxicity.
Everyday: A protein that directs immune cells to attack myeloma cells.
Targets: ["BCMA","CD3"]
Revenue History
PeriodRevenue ($M)
2025$1,500M
2024$549M
Programs (1)
IndicationStageKey StudyRegional Status
R/R MMAPPROVEDMajesTEC-1[{"stage":"APPROVED","region":"US","approval_date":"2022-10-25"},{"stage":"APPRO
Notes
First BCMA-targeting bispecific for R/R MM. Competes with CAR-T and other bispecifics. Genmab receives royalties from J&J. CRS management required.
Data from Supabase · Updated 2026-03-24